Efforts to soon access potential cancer vaccines to bring to Vietnam

Mr. Kirill Dmitriev, General Director of the Russian Direct Investment Fund (RDIF), exchanged cooperation documents with Mr. Ngo Chi Dung, Chairman and General Director of VNVC Vaccine Company, in the presence of Russian President Putin and General Secretary To Lam. Photo: VGP/Hoang Thong Nhat

The document was signed between the Russian Direct Investment Fund and VNVC Vaccine Company in the presence of the two heads of Vietnam and Russia within the framework of the official visit to the Russian Federation by General Secretary To Lam from May 8 to 11, on the occasion of the 80th anniversary of Victory Day in the Great Patriotic War and the 75th anniversary of the establishment of diplomatic relations between Vietnam and Russia.

Under this cooperation, the two sides will discuss to establish a foundation for deep cooperation on high technology in the field of biomedicine, focusing on research, investment, technology transfer and trade of biological drugs and high-tech vaccines. In particular, VNVC's top expectation is to soon bring to Vietnam a potential cancer treatment vaccine based on the most modern mRNA technology that Russia has recently announced.

In addition to this important cooperation document, VNVC also signed a cooperation agreement with the Gamaleya National Research Center for Epidemiology and Microbiology on scientific research cooperation and biotechnology development. Research topics will be implemented in the near future.

VNVC has also signed a contract with the Russian pharmaceutical group Binnopharm, one of the largest pharmaceutical manufacturers in Russia.

Immediately after signing, VNVC will begin scientific exchange activities with scientists from many Russian research institutes and high-level hospitals to receive technology transfer for research, testing and production of vaccines using mRNA technology.

In particular, research and development of vaccine production according to the "complete, closed cycle" model in Vietnam, focusing on pharmaceutical products that are Binnopharm's strengths, along with other important Russian pharmaceutical products, specializing in the field of high-tech cancer diagnosis and treatment.

In December 2024, the National Medical Research Center for Radiology under the Russian Ministry of Health announced that Russia is researching and developing a cancer vaccine using modern mRNA technology.

Previously, in December 2024, the National Medical Research Center for Radiology under the Russian Ministry of Health announced that the country was researching and developing a potential lung cancer vaccine, produced using advanced mRNA technology.

Strengthening scientific exchange and technology transfer between the two countries

Also according to the cooperation agreement between RDIF and VNVC, potential Russian mRNA technology vaccines will be brought to Vietnam by VNVC soon from the early stage of clinical trials, so that patients have the opportunity to access more of the world's leading modern solutions with a very high success rate after treatment.

In addition, Russia's implementation of clinical trials of biological drugs and advanced technology vaccines in Vietnam also helps the registration, licensing and commercialization of products to be more convenient and faster as soon as good results are achieved.

The cooperation agreement between VNVC and prestigious Russian agencies and organizations in the field of healthcare, investment, cooperation and technology transfer has opened up opportunities for Vietnam to have early and comprehensive access to new Russian research and inventions in the field of healthcare.

This important cooperation between VNVC and the world's leading major partner continues to affirm the remarkable growth of Vietnamese healthcare on the world healthcare map, contributing to enhancing the country's position in the new era. This cooperation is considered a concrete action, realizing the policy from Resolution 57-NQ/TW of the Politburo on breakthroughs in science, technology development, innovation and national digital transformation.

Kirill Dmitriev, Special Representative of the President of Russia for Foreign Economic Affairs and Investment, General Director of the Russian Direct Investment Fund (RDIF), said that the cooperation framework announced today will play an important role in enhancing scientific exchanges and technology transfer between the two countries to develop pioneering healthcare products.

Highly appreciating the cooperative relationship with prestigious Russian agencies, Mr. Ngo Chi Dung, Chairman of the Board of Directors and CEO of VNVC Vaccine Company, affirmed that this is an important milestone, opening up opportunities for Vietnam to access and test vaccines using the most advanced mRNA technology that Russia is promoting research and development.

"The two sides will discuss to open up opportunities for Vietnam to have early access to Russia's potential mRNA cancer vaccine, not only for clinical trials and product commercialization, but also for production at the VNVC Vaccine and Biological Products Factory in Long An," Mr. Ngo Chi Dung emphasized.

Previously, VNVC Vaccine Company and its member unit, Tam Anh General Hospital System, had many research cooperations with prestigious international organizations and health agencies on vaccines and new drugs, aiming to improve treatment and enhance people's health, prevent non-communicable diseases such as cancer, cardiovascular diseases and infectious diseases such as pneumococcus, respiratory syncytial virus; clinical research on oral immunotherapy drugs for cancer treatment; signed cooperation agreements to produce high-quality vaccines with the world's leading pharmaceutical companies...

HM

Source: https://baochinhphu.vn/no-luc-som-tiep-can-vac-xin-ung-thu-tiem-nang-dua-ve-viet-nam-102250511094532205.htm